MNCs Continue Patent Filings In India Despite Strong Local Challenges
This article was originally published in PharmAsia News
Multinational pharmaceutical companies continue to file for Indian drug patents despite strong challenges waged by local drug makers. Many of the new filings are for drugs in the same class as Gleevec (imatinib mesylate) a Novartis drug the subject of a long-lasting court fight. AstraZeneca, Bayer, Bristol Myers Squibb, GlaxoSmithKline and Pfizer have filed applications for six drugs considered a new generation of medicines in the same class as Gleevec for treating chronic myeloid leukemia. For instance, Novartis has filed for a patent for Tasigna (nilotinib monohydrate) to treat patients resistant or tolerant to Gleevec. (Click here for more
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.